News for Cyclacel Pharmaceuticals, Inc. (CYCCP)

Shares of Block, Inc. XYZ rose sharply in pre-market trading ahead of the S&P 500 debut of the Jack Dorsey-founded fintech company. Block will replace Hess Cor...

U.S. stocks traded mixed this morning, with the Nasdaq falling around 0.1% on Wednesday. Following the market opening Wednesday, the Dow traded up 0.08% to 44,...

Cyclacel Pharmaceuticals (CYCC) addresses recent unusual stock price volatility. No material changes in the company's operations or financial conditions

Cyclacel Pharmaceuticals (CYCC) has reported that it is unaware of any significant changes in its business operations or financial status that would explain the

Kuala Lumpur, Malaysia, July 16, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. ( CYCC, CYCCP; ”œCyclacel” or the ”œCompany”), a biopharmaceut

Minnesota-based Nuwellis, Inc. (NUWE) is up over 147 percent in Wednesday's pre-market trading. The following are some of the other stocks making big moves in Wednesday's pre-market trading.

Pennsylvania-based Longevity Health Holdings, Inc. (XAGE) is up over 93 percent in Tuesday's pre-market trading. The following are some of the other stocks making big moves in Tuesday's pre-market trading.

Pennsylvania-based Longevity Health Holdings, Inc. (XAGE) is up over 93 percent in Tuesday's pre-market trading. The following are some of the other stocks making big moves in Tuesday's pre-market trading.

Shares of The Trade Desk, Inc. TTD rose sharply in pre-market trading following the announcement of its inclusion in the S&P 500 index. This development comes ...

Cyclacel Pharmaceuticals (CYCC) amends exchange agreement with FITTERS Diversified Berhad, adding $1 million cash consideration. The transaction involve

Kuala Lumpur, Malaysia, July 07, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. ( CYCC, CYCCP; ”œCyclacel” or the ”œCompany”), a biopharmaceut

- Fibrolamellar hepatocellular carcinoma (FLC) has no approved treatment and occurs mostly in adolescents and young adults - KUALA LUMPUR, Ma

BERKELEY HEIGHTS, N.J., July 02, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; 'Cyclacel” or the 'Company”), a biopharmaceutical company developing innovative medicines, today announced that it expects to implement a 1-for-15 reverse stock split on its shares of common stock effective July 7, 2025, with trading to begin on a split-adjusted basis at the market open on that day. Trading in the shares of common stock will continue on The Nasdaq Capital Market under the symbol 'CYCC”. The new CUSIP number for the shares of common stock following the reverse stock split is 23254L876.

Cyclacel Pharmaceuticals raises $3 million through a strategic private placement. Analyst price target suggests a potential 193.34% upside. Current b

KUALA LUMPUR, June 20, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (”œCyclacel”) ( CYCC, CYCCP), a biopharmaceutical company that develops inn

Cyclacel Pharmaceuticals (CYCC) raises $3 million through a private placement of convertible Series F Preferred Stock. The financing extends Cyclacel's

Cyclacel Pharmaceuticals (CYCC) has successfully met the requirements set by Nasdaq to be in compliance with Listing Rule 5550(a)(2). The company received offic

KUALA LUMPUR, MALAYSIA, June 03, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. ( CYCC, CYCCP; ”œCyclacel” or the ”œCompany”), a biopharmaceut

Cyclacel Pharmaceuticals (CYCC) regains compliance with Nasdaq's minimum bid price requirement. CYCC's stock maintained a closing bid price of at least